Table 1 Demographic, clinical and surgical details of all 11 patients
Clinical scores
Patient no./age (years)/sexMedications*Disease duration (years)HAQDASESRCRPSw/Td jntType of surgical procedure
1/61/FMTX, SSZ111.54.304N/A8/33Right-wrist arthrodesis
2/61/MMTX, pred, LEF210N/AN/AN/A5/10Lapidus precedure left foot, modified Hibbs transfer, 3rd metatarsal shortening, 4th toe PIP fusion, 5th toe flexor tenotomy
3/65/FMTX, pred, HCQ281.884.201654/27Arthrodesis 4th and 5th tarsometatarsal joints
4/53/FMTX, pred, LEF153.255.17378114/28Arthroplasty right ring and middle PIP joints
5/59/FMTX254.252.961175/9Right lapidus procedure, release and reduction MTP joints 2 and 5, PIP joint fusion toes 2–5
6/64/F†MTX, pred, HCQ430.632.87425/12Left 1st metatarsal osteotomy, right 4th toe PIP arthrodesis
7/57/F†MTX, pred, SSZ HCQ152.885.87121426/34Bilateral forefoot arthroplasties (resection of metatarsal heads 2–5, fusion 1st MTP joint)
8/77/FPred, cyclo62.385.75533221/28Arthrodesis left naviculocuneiform, intercuneiform, 2nd and 3rd TMT joints
9/59/FMTX, pred, SSZ292.753.1243342/8Right foot 1st MTP fusion and excision of lesser metatarsal heads 2–5
10/49/F†SSZ, pred, HCQ, MTX261.885.298432/22Arthroplasty left hand, MCP joints 2–5
11/50/F†HCQ241.883.57313014/8Left metatarsal scarf osteotomy, osteotomies 2nd and 4th MTP joints
  • *Medications: all patients on NSAIDs, MTX, methotrexate; pred, prednisone (10 mg or less); HCQ, hydroxychloroquine; SSZ, sulfasalazine; LEF, leflunomide; cyclo, ciclosporine; †histopathology available; see table 2. DAS, disease activity score; ESR, erythrocyte sedimentation rate (mm/h); HAQ, health assessment questionnaire; PIP, proximal interphalangeal joints; MTP, metatarsophalangeal joints; Sw/Td, swollen and tender joints; N/A, not available.